This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fragasso, G. Articles by Margonato, A. Search for Related Content PubMed PubMed Citation Articles by Fragasso, G. Articles by Margonato, A. Related Collections Related Article

A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure

Gabriele Fragasso, MD^_*,_*, Altin Palloshi, MD^_*, Patrizia Puccetti, MD^_*, Carmen Silipigni, MD^_*, Alessandra Rossodivita, MD, Mariagrazia Pala, MD, Giliola Calori, MDPhD^_*, Ottavio Alfieri, MD^_* and Alberto Margonato, MD, FESC^_*

^_* Clinical Cardiology-Heart Failure Unit
Cardiac Surgery, Istituto Scientifico-Universita Vita/Salute San Raffaele, Milan, Italy

View larger version (12K): [in a new window]   Figure 1 Effect of trimetazidine and conventional therapy alone on quality of life (0% to 100%), at baseline (solid bars) and at follow-up (open bars). Compared with patients treated with conventional therapy alone, in whom a clear trend toward deterioration was observed, those treated with trimetazidine showed a significant improvement of quality of life.

View larger version (19K): [in a new window]   Figure 2 Individual effects of trimetazidine (A) and conventional therapy alone (B) on left ventricular ejection fraction (LVEF), at baseline, and at follow-up. Trimetazidine significantly improved LVEF, whereas a trend toward a decline in left ventricular function was observed in patients treated with conventional therapy alone.